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Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive 
immune responses trigger life-threatening cytokine rel ase syndrome (CRS) which can result in 
overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), 
interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests 
that the modulation of systemic immune responses may have a potential role in the treatment of 
patients with COVID-19. Given the importance of theissue and the lack of therapeutic treatment or 
vaccine; anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the 
alleviation of hyper-inflammation status in these patients. In this mini-review, we addressed the 
inflammatory pathways of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 
its relationship with the host cytokine storm. Furthe more, the proposed therapeutic options to revers 
hyper-inflammation in infected patients were mentioed. 
 




Prevalence, Taxonomy and Structural Biology of SARS-CoV-2 
 
In December 2019, coronavirus disease 2019 (COVID-19) outbreak commenced in Wuhan, Hubei 
province, China and spread rapidly to other provinces in China and several countries all over the 
world (1). This infectious disease has been identifi d by the World Health Organization (WHO) as a 
global pandemic. Based on the WHO declaration on January 30, 2020, the outbreak of COVID-19 is 
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a global health emergency of international concerns due to its capability of rapid human-to-human 
transmission (2). The mortality rate of COVID-19 is terribly growing worldwide. As of April 16, 
2020, this severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected a total of 
2,060,927 confirmed cases with 134,354 deaths in more than 200 countries and territories (3). 
SARS-CoV-2 is a novel β-coronavirus that belongs to the subfamily Orthocornavirinae in the family 
of Coronaviridae, in the order of Nidovirales. The SARS-CoV-2 is an enveloped positive-sense 
single-stranded RNA (+ssRNA) virus with 4 major proteins in its structure, including the spike (S) 
protein (which mediates attachment to the host receptor and subsequent fusion of the virus and cell 
membrane), the membrane (M) protein, the envelope (E) protein, and the nucleocapsid (N) protein 
(4). Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory 
syndrome coronavirus (MERS-CoV) are other β-coronavirus widespread epidemics in 2002 and 
2012, respectively (5). Based on recent pieces of evidence, SARS-CoV-2 has approximately 79–82% 
similarity to human SARS-CoV genome at the nucleotide sequences. It has been supposed that the 
SARS-CoV-2 virus, similar to SARS CoV, uses the angiotensin-converting enzyme 2 (ACE2) as the 
receptor for entering host cells (6). ACE2 receptors are expressed in the membrane of various cells in 
the human body, including type II alveolar epithelial cells of the lung (7). Accordingly, it is expectd 
that the bilateral diffuse alveolar injury with cytodiagnosis of myxoid fibroma exudate is the first 
pathological finding of COVID-19 (8). Furthermore, kidney, intestine, heart, and blood vessels are 
the other organs expressing ACE2 receptor, and this may describe why some patients with COVID-
19 (~46%) experience renal, gastrointestinal, and car iovascular problems (9,10). The spike 
glycoprotein (S) mediates virus entry via binding to the host cell’s ACE2 receptor and membrane 
fusion (11). It is supposed that the interaction of the viral particle with specific proteins on the host 
cell surface and entering of the virus to human cells are the main triggers, which initiate infection a d 
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inflammatory cascade through various mechanisms with consequent release of pro-inflammatory 
cytokines (6,12). To the best of our knowledge the main clinical features of patients with COVID-19 
consist of a) high concentration of inflammatory parameters such as C-reactive protein (CRP) and 
pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, tumor necrosis factor-α (TNFα), etc.; 
b) Infiltration of immune cells to the lung lesion mostly monocytes and macrophages; c) Destruction 
of the immune system owing to atrophy of spleen and lymph nodes; d) Reduction of lymphocytes 
(lymphopenia) in lymphoid organs; and ultimately; e) Vasculitis, hypercoagulability, and multiple 
organs damage (13). 
The term “cytokine release syndrome” (CRS) or cytokine storm syndrome (CSS) was defined as a 
systemic inflammatory response, which can occur by a variety of factors, including infections and 
certain drugs (14). In this review, we addressed th inflammatory pathways of SARS-CoV-2 and its 
relationship with the host cytokine storm. Furthermo e, the proposed therapeutic options to reverse 
hyper-inflammation in infected patients were mentioed. The understanding of molecular 
mechanisms involved in this viral infection provides new insights into the more appropriate 
management of COVID-19. 
 
Inflammatory Pathways of SARS-CoV-2 
 
Inflammation is the immediate body’s defense against infection or trauma injury; however, it can be 
considered a double-edged sword. Inflammation with activation of both innate and adaptive immune 
responses can enhance host immunity against infection, while excessive immune responses following 
some pathogens such as the influenza virus, trigger life-threatening CSS in the host, which can result 
in excessive production of pro-inflammatory cytokines and eventually, leads to death (15,16). 
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Cytokines are a group of secreted proteins that are released by some cells with specific effects on the 
development, differentiation, and regulation of immune cells (17). 
According to recent studies, SARS-CoV-2 stimulates innate and adaptive immune systems after 
binding to type II alveolar epithelial cells of the lung; the over-stimulated response of the immune 
system may cause more damage to the host cells than the SARS-CoV-2 as a foreign invader (18). 
Toll-like receptors (TLRs), a subfamily of pattern recognition receptors (PRRs), can recognize 
“danger signals” such as SARS-CoV-2 viruses in the extracellular milieu and endosomes and mediate 
the inflammatory signaling cascade that leads to the activation and production of inflammatory 
cytokines (19). Inflammasomes are multi-protein cytosolic molecular platforms comprised of 
caspase-1, Nod-like receptors (NLRs; i.e., NLRP1, NLRP3, and NLRC4) and apoptosis-associated 
speck-like protein containing a CARD (Caspase activting and recruitment domain or ASC) adaptor 
protein (20). The cleavage and secretion of pro-IL-1β and pro-IL-18 into bioactive cytokines, caused 
by the activation of the NLRP3 inflammasome, is a powerful determinant in the inflammatory status 
(21). On the other hand, TLR activation following a viral infection can induce the production of IL-6 
by monocytes and macrophages. TLRs, TNFα, and IL-1β are known as the main stimulators for the 
synthesis of IL-6 (22). IL-6 is the main regulator of T cells. It can promote the development and 
function of Th17 cells (a population of CD4+ T helper cells), which may serve as pro-inflammatory 
self-reactive T cells (23). In addition, IL-6 can induce the production of some acute phase proteins 
such as CRP (24). Figure 1 shows the proposed pathway for inducing cytokine storm following 
SARS-Cov-2 infection. 
The results of a recent meta-analysis of nine studies showed that the IL-6 levels were significantly 
increased in COVID-19-infected patients with severe conditions (SMD = 0.71, 95%CI –0.31 to 1.12, 
p = 0.0005) (25). Ruan and colleagues showed the elevat d level of IL-6 in critically ill individuals 
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with COVID-19 (26). Similarly, other reports also established the increased level of IL-6 in patients 
with confirmed COVID-19 pneumonia and it has been shown that the level of IL-6 has a positive 
correlation with the severity of the disease (4,27,28). 
In another study, Huang C, et al. (29) reported that t e plasmatic concentration of IL-2, IL-7, 
interferon-gamma (IFN-γ), granulocyte-colony stimulating factor (GCSF), interferon γ-induced 
protein 10 kDa (IP-10), monocyte chemo-attractant pro ein 1 (MCP1), macrophage inflammatory 
proteins (MIP), and TNF-α were higher in 41 admitted severe patients with confirmed COVID-19 in 
Wuhan. Interestingly, they found that SARS-CoV-2 infection also initiated an increased secretion of 
Th2-related cytokines such as IL-4 and IL-10 for suppressing hyper-inflammation. The same 
researchers in another multicenter cohort study report d an increased concentration of IL-6 in non-
survival group of patients with COVID-19 (30). 
Interleukin-1 family with different pro-inflammatory roles has been considered in patients with 
COVID-19 due to their important role in CSS symptoms, including fever, edema, and finally, organ 
dysfunction or death. Interestingly, Huang C, et al. reported an elevated level of IL-1β in severe 
patients with COVID-19 (29). 
 
Suggested Therapeutic Options to Reverse Hyper-inflammation in Patients with COVID-19 
 
Modulation of systemic immune responses may have a potential role in the treatment of patients with 
COVID-19. Given the importance of the issue and the lack of a vaccine or proven effective therapy, 
anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the 
alleviation of hyper-inflammation as the main leading cause of severe adult respiratory distress 
syndrome (ARDS) in patients with COVID-19 (31,32). 
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Importantly, some clinical findings in China have shown that Tocilizumab (a monoclonal anti-IL-6 
receptor) can significantly improve oxygenation and may be considered a promising therapeutic 
option in patients with COVID-19 who are at the risk of cytokine storm (33). Another small sample 
clinical trial in China has indicated good efficacy of Tocilizumab treatment in severe COVOD-19 
patients (34). A case report from France reported successful treatment of Covid-19-related respiratory 
failure using Tocilizumab in a patient with cancer (35). According to previous studies, Tocilizumab 
can reduce the affinity of IL-6R to IL-6 by binding to IL-6R and soluble IL-6R, thereby inhibiting the 
CSS (18). Tocilizumab as a recombinant humanized monocl nal antibody has been approved for the 
treatment of patients with severe CSS (36,37). 
Anakinra (recombinant interleukin-1 receptor antagonist: IL-1Ra) is another therapeutic option with 
IL-1 blockade properties. A group of American researchers suggested that continuous intravenous 
Anakinra infusions might have significant survival benefits owing to possibly reversing the cytokine 
storm in patients with COVID-19 (38). Previously, Shakoory B, et al. (39) claimed that the 
administration of Anakinra intravenously at a dose f 2.0 mg/kg/h for 72 h could significantly reduce 
the 28 d mortality in 484 patients with severe sepsis. Though the exact role of IL-1 in the 
pathogenesis of CSS is unclear, it seems that IL-1 receptor blockade may aid in better control of the 
inflammatory process. According to the previous repo ts, Anakinra is a biopharmaceutical drug with 
a wide therapeutic range, and high safety (40). Currently, Anakinra has been approved by the food 
and drug administration (FDA) for the treatment of a variety of auto-immune diseases, including 
rheumatoid arthritis as well as neonatal-onset multisys em inflammatory disease (41). 
TNFα is another main cytokine in many inflammatory diseas s. The elevated level of TNFα in blood 
and tissues of patients with COVID-19 has been indicated in previous reports (42,43). The potential 
role of anti-TNF therapy has been considered recently for reducing inflammation in COVID-19. 
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Some anti-TNF antibodies such as infliximab or adalimumab have been suggested for modulating 
hyper-inflammatory responses in patients with COVID-19. Based on clinical recent studies, TNF 
blockade, as an amplifier of inflammation, causes a rapid reduction in IL-6 and IL-1 concentrations 
(44,45). Feldmann and colleagues have postulated that a single infusion of anti-TNF antibody in the 
early stage of infection can be effective in the trea ment of patients with COVID-19 (42). However, 




Based on available evidence, targeting the cytokine storm should be considered in the current 
COVID-19 outbreak in patients with severe disease for alleviation patients’ inflammatory status. 
However, future clinical trials are required to gain more definite conclusion regarding the potential 
mechanistic connections between blockade of inflammtory cytokines (i.e. IL-6, IL-1 and TNFα) and 
COVID-19 management in severe patients. 
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Figure 1. A proposed pathway for inducing cytokine storm following SARS-Cov-2 infection. SARS 
CoV-2 virus uses the angiotensin-converting enzyme 2 (ACE2) as the receptor for entering the cells. 
After entering to type II alveolar epithelial cells of the lungs, SARS CoV-2 triggers life-threatening 
cytokine release in the host, which can result in excessive levels of pro-inflammatory cytokines 
production including IL-6, TNF-α and IL-1β. Type II AEC: type II alveolar epithelial cells; RBC: red 
blood cells; IL: interleukin; TNF α: tumor necrosis factor α; IFN-γ: interferon-gamma, GCSF: 
granulocyte-colony stimulating factor, IP-10: interferon γ-induced protein; MCP1: monocyte chemo-
attractant protein 1; MIP: macrophage inflammatory proteins; Th: T helper 
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• The outbreak of COVID-19 (coronavirus) has been identified by the World 
Health Organization as a global pandemic. 
• There is an urgent need to identify safe and effective drugs or potential 
adjuvant therapy in this regard. 
• Inflammatory cytokines blockade proposed to be a novel therapeutic 
approach to reverse hyper-inflammatory status in COVID-19 infected 
patients.  
